The Neuroprotective Effects of Astaxanthin: Therapeutic Targets and Clinical Perspective
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
As the leading causes of human disability and mortality, neurological diseases affect millions of people worldwide and are on the rise. Although the general roles of several signaling pathways in the pathogenesis of neurodegenerative disorders have so far been identified, the exact pathophysiology of neuronal disorders and their effective treatments have not yet been precisely elucidated. This requires multi-target treatments, which should simultaneously attenuate neuronal inflammation, oxidative stress, and apoptosis. In this regard, astaxanthin (AST) has gained growing interest as a multi-target pharmacological agent against neurological disorders including Parkinson’s disease (PD), Alzheimer’s disease (AD), brain and spinal cord injuries, neuropathic pain (NP), aging, depression, and autism. The present review highlights the neuroprotective effects of AST mainly based on its anti-inflammatory, antioxidative, and anti-apoptotic properties that underlies its pharmacological mechanisms of action to tackle neurodegeneration. The need to develop novel AST delivery systems, including nanoformulations, targeted therapy, and beyond, is also considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxidative stress, aging, and diseases
Liguori, I., Russo, G., Curcio, F., Bulli, G., Aran, L., Della-Morte, D., Gargiulo, G., Testa, G., Cacciatore, F., Bonaduce, D., et al. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s158513 · Cited by 3,979 · cited 1×
“The oxidative stress increases with aging and the brain become significantly more vulnerable to neurodegenerative disease [100,101].”
BackgroundThe role of inflammation in depression: from evolutionary imperative to modern treatment target
Miller, A. H., & Raison, C. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.5 · Cited by 3,942
Sies, H., Berndt, C., & Jones, D. P. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045037 · Cited by 3,520 · cited 2×
“While glutathione reductase and thioredoxin reductase protect the complexes stability of Keap1-Nrf2 as well as IκB-NF-κB, cytosolic H2O2 cause dissociation of the complexes and allows the nuclear transportation of NF-κB and Nrf2 [20,21].”
BackgroundCyclodextrins and their uses: a review
Del Valle, E. M. M. (2004) · Process Biochemistry · doi:10.1016/s0032-9592(03)00258-9 · Cited by 3,375 · cited 2×
“i l - l t st st ss i ti s r s lt i t tr ll r l s f t st, i cr se f its r ilicity, st ilit i st li t, heat, and oxygen [1 6], and bioavailability [167], as well as an improvement in the antioxidation potential of the guest [168].”
BackgroundNeuroglial activation and neuroinflammation in the brain of patients with autism
Vargas, D. L., Nascimbene, C., Krishnan, C., Zimmerman, A. W., & Pardo, C. A. (2005) · Annals of Neurology · doi:10.1002/ana.20315 · Cited by 2,149
New approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589 · cited 1×
“In the treatment of depression, monoamine regulation still plays a crucial role and brings up tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and selective–norepinephrine reuptake inhibitors (…”
BackgroundThe role of oxidative stress in neurodegenerative diseases
Kim, G. H., Kim, J. E., Rhie, S. J., & Yoon, S. (2015) · Experimental Neurobiology · doi:10.5607/en.2015.24.4.325 · Cited by 1,355
Neuropathic pain: an updated grading system for research and clinical practice
Finnerup, N. B., Haroutounian, S., Kamerman, P., Baron, R., Bennett, D. L. H., Bouhassira, D., Cruccu, G., Freeman, R., Hansson, P., Nurmikko, T., et al. (2016) · Pain · doi:10.1097/j.pain.0000000000000492 · Cited by 1,332 · cited 1×
“NP is caused by a disease or a lesion in the somatosensory nervous system [62], with an estimated cost of 40 billion dollars per year in the U.”
BackgroundAstaxanthin: a review of its chemistry and applications
Higuera-Ciapara, I., Félix-Valenzuela, L., & Goycoolea, F. M. (2006) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408690590957188 · Cited by 1,287 · cited 1×
“This property highlights its unique potential to combat aging [4,107].”
BackgroundA review on the use of cyclodextrins in foods
Astray, G., Gonzalez-Barreiro, C., Mejuto, J. C., Rial-Otero, R., & Simal-Gándara, J. (2009) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2009.01.001 · Cited by 911
Elevated immune response in the brain of autistic patients
Li, X., Chauhan, A., Sheikh, A. M., Patil, S., Chauhan, V., Li, X.-M., Ji, L., Brown, T., & Malik, M. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.12.002 · Cited by 786
Jones, D. P., & Sies, H. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6247 · Cited by 647
Metabolic Syndrome, Aging and Involvement of Oxidative Stress
Bonomini, F., Rodella, L. F., & Rezzani, R. (2015) · Aging and Disease · doi:10.14336/ad.2014.0305 · Cited by 599
Neuropathology of Infantile Autism
Kemper, T. L., & Bauman, M. (1998) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199807000-00001 · Cited by 585
Neuropathological findings in autism
Palmen, S. J. M. C. (2004) · Brain · doi:10.1093/brain/awh287 · Cited by 527
Immune mechanisms linked to depression via oxidative stress and neuroprogression
Bakunina, N., Pariante, C. M., & Zunszain, P. A. (2015) · Immunology · doi:10.1111/imm.12443 · Cited by 444
Stereological Analysis of Amygdala Neuron Number in Autism
Schumann, C. M., & Amaral, D. G. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1285-06.2006 · Cited by 413 · cited 1×
“Age-related and progressive neuronal pathology and neuronal loss in cerebellar Purkinje [115] or amygdala [116] cells in individuals with autism [117] are all representative of a neurodegenerative process [118–121].”
BackgroundElevation of Tumor Necrosis Factor-Alpha in Cerebrospinal Fluid of Autistic Children
Chez, M. G., Dowling, T., Patel, P. B., Khanna, P., & Kominsky, M. (2007) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2007.01.012 · Cited by 317 · cited 1×
“There is also a close link between autism and the release of proinflammatory cytokines [122,123].”
BackgroundNicotinic receptor abnormalities in the cerebellar cortex in autism
Lee, M. (2002) · Brain · doi:10.1093/brain/awf160 · Cited by 232
Perluigi, M., Sultana, R., Cenini, G., Di Domenico, F., Memo, M., Pierce, W. M., Coccia, R., & Butterfield, D. A. (2009) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200800161 · Cited by 196 · cited 1×
“The brain has rich irrigation with blood vessels, very high oxygen consumption, and lower antioxidant capability, which it is very susceptible to oxidative damage [46].”
BackgroundThomas, J., Thomas, C. J., Radcliffe, J., & Itsiopoulos, C. (2015) · BioMed Research International · doi:10.1155/2015/172801 · Cited by 173
Age and Alzheimer’s disease gene expression profiles reversed by the glutamate modulator riluzole
Pereira, A. C., Gray, J. D., Kogan, J. F., Davidson, R. L., Rubin, T. G., Okamoto, M., Morrison, J. H., & McEwen, B. S. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.33 · Cited by 116 · cited 1×
“Hippocampal neurogeneration is associated with learning and memory processes [102].”
BackgroundKomaki, A., Karimi, S. A., Salehi, I., Sarihi, A., Shahidi, S., & Zarei, M. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.02.008 · Cited by 52 · cited 1×
“Many studies aimed at exploring the relationship between diet and their effects on cognitive ability [56,57].”
Background
Cited by
Shehata, M. K., Ismail, A. A., & Kamel, M. A. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s417928 · Cited by 55
Metadata
- Authors
- Fakhri, S., Yosifova Aneva, I., Farzaei, M. H., & Sobarzo-Sánchez, E.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2019-07-20
- Volume
- 24
- Issue
- 14
- Pages
- 2640
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2963532412
- Cited by
- 165
- References
- 23
- FWCI
- 6.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.